Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration

(Boston) - Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

Read the whole article on Science Blog

More from Science Blog